Bristol-Myers Squibb News
Most Popular Bristol-Myers Squibb Story
BMS to pay Exelixis $240M for cancer drugs
Bristol-Myers Squibb has snatched up two Exelixis programs that GSK left behind when it ended its six-year collaboration with Exelixis. The development deal covers two cancer therapies--Exelixis'... Read more...
Latest Headlines
- December 12, 2008
- December 8, 2008
- November 24, 2008
- October 1, 2008
- September 29, 2008
- September 24, 2008
- September 23, 2008
- September 16, 2008
- September 12, 2008
- September 11, 2008
- September 10, 2008
- September 9, 2008
- August 28, 2008
- August 27, 2008
- August 20, 2008
- August 11, 2008
- August 4, 2008
- July 31, 2008
- July 8, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
